Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ART5803 Compared with Placebo in Healthy Participants

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Double-blind, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ART5803 Compared with Placebo in Healthy Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ART-5803 (Primary)
  • Indications Anti-N-methyl-D-aspartate-receptor-encephalitis; Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Arialys Therapeutics

    • Most Recent Events

    • 26 Feb 2025 According to an Arialys Therapeutics media release, study is being conducted in collaboration with Nucleus Network inMelbourne, Australia.
    • 26 Feb 2025 According to an Arialys Therapeutics media release, trial has enrolled 40subjects in the SAD cohorts and is expected to enroll approximately 24 subjects in the MAD cohorts.
    • 26 Feb 2025 Results presented in an Arialys Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top